Rutgers Global Health Institute’s director discusses how rejecting scientific facts can undermine progress in public health – and how the medical profession can further public understanding of science
Vaccinating asthmatic pre-schoolers against influenza could dramatically reduce their risk of being hospitalized after an attack, Canadian researchers find.
This month's tip sheet from Fred Hutch includes information about cancer care delivery and costs, partnering with Microsoft, understanding/changing cancer's genetics and a Mt. Everest climb for cancer research fundraising. To pursue any of these story ideas, please contact the individual listed for each.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells’ response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma.
A new study shows a rapid rise in the percentage of hospitals that require their workers to be vaccinated against influenza – except among hospitals that focus on treating the nation’s military veterans. The percentage of Veterans Affairs hospitals that have a flu vaccine mandate rose from 1 percent in 2013 to 4 percent in 2017. But at the same time, the percentage of non-VA hospitals requiring shots rose from 44 percent to nearly 70 percent.
An international study led by researchers at UCLA has found that a personalized vaccine targeting glioblastoma, the deadliest form of brain cancer, may help people live longer. Nearly 30 percent of people in the current trial have now survived for at least three years after receiving the vaccine.
A study showing that pneumococcal vaccination produces a lasting antibody response in preterm infants has been named winner of the inaugural ESPID-PIDJ Award, recognizing the best paper submitted to The Pediatric Infectious Disease Journal (PIDJ) by a member of The European Society for Paediatric Infectious Diseases (ESPID). The Pediatric Infectious Disease Journal, the official journal of the ESPID, is published in the Lippincott portfolio by Wolters Kluwer.
Antibody therapy developed at the Uniformed Services University of the Health Sciences as a treatment against the Nipah and Hendra viruses has led to an agreement announced today between USU, the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), Profectus BioSciences, Inc., and Emergent BioSolutions, Inc., for development of a human vaccine against the two deadly viruses. The USU-HJF Joint Technology Transfer Office licensed the technology, which is supported by the Coalition for Epidemic Preparedness Innovations (CEPI).
In this issue, find research on gun ownership, support for gun violence prevention, suicide risk and gun ownership, refugee mental health, HPV vaccine and indoor tanning.
UNC School of Medicine researchers have delineated the details of one major barrier to a promising vaccine. It’s something we all have – a natural body temperature of about 98.6 degrees.
A new study shows that a kind of E. coli most associated with “travelers’ diarrhea” and children in underdeveloped areas of the world causes more severe disease in people with blood type A. The bacteria release a protein that latches onto intestinal cells in people with blood type A, but not blood type O or B. A vaccine targeting that protein could potentially protect people with type A blood against the deadliest effects of E. coli infection.
Value in Health, the official journal of ISPOR, announced today the publication of new research suggesting that subsidized or part-payment from the Hong Kong government should be considered to help foster mothers’ willingness to pay for human papillomavirus (HPV) vaccination for their daughters.
Research conducted in vitro shows two human antibodies made in response to vaccination against one hemorrhagic fever virus can disarm a related virus, for which there is currently no vaccine. The proof-of-principle finding identifies a common molecular chink in the two viruses’ armor that renders both vulnerable to the same antibodies. The results set the stage for a single vaccine and other antibody-based treatments that work against multiple viral “cousins” despite key differences in their genetic makeup. Such therapies can alleviate challenges posed by current lack of vaccines and prevent outbreaks of viral hemorrhagic fevers.
Click here to go directly to the Cancer News Source
Anthrax, plague and tularemia are three potent agents terrorists would be likely to use in an attack, according to the Centers for Disease Control and Prevention. Each is highly and quickly lethal to humans. But there are no licensed vaccines for tularemia and plague, and although there is an anthrax vaccine, it requires a burdensome immunization schedule and has severe side effects.
With the new funding from the Gates Foundation, the Scripps Research team will expand their studies of neutralizing antibodies.
New research shows small, New World monkeys called marmosets may be an important animal model for emerging viruses with the potential for harmful effects on fetuses
By stretching the amount of time proteins can be simulated in their natural state of wiggling and gyrating, a team of researchers at Colorado State University has identified a critical protein structure that could serve as a molecular Achilles heel able to inhibit the replication of dengue virus and potentially other flaviviruses such as West Nile and Zika virus.
The Sabin Vaccine Institute has awarded Paul Offit, MD, of Children’s Hospital of Philadelphia, the 2018 Albert B. Sabin Gold Medal. Sabin recognized Dr. Offit as co-inventor of an oral rotavirus vaccine and for his leadership as one of the United States’ most vocal and dedicated advocates for immunization.
Researchers have developed a vaccine for one of the most dangerous types of synthetic cathinones, or bath salts. The vaccine blunts the illegal stimulant’s effects on the brain, which could help recovering drug users who experience a relapse.
This new insight may allow researchers to design drugs that improve immune responses to vaccines.
ASU intervention study shows promising results for HPV-vaccination education program for parents
A new paper published in Circulation by researchers at La Jolla Institute for Allergy and Immunology reports successful vaccination of atherosclerotic mice with a small chunk of protein snipped out of "bad cholesterol." Vaccination reduced plaque levels in test mice, and other experiments with human blood samples identified the class of T cells likely responsible for positive outcomes. The paper suggests that a comparable strategy could form the basis of a human vaccine.
A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.
A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response. The trial, conducted in advanced ovarian cancer patients, was a pilot trial aimed primarily at determining safety and feasibility, but there were clear signs that it could be effective: About half of the vaccinated patients showed signs of anti-tumor T-cell responses, and those “responders” tended to live much longer without tumor progression than those who didn’t respond. The study is published today in Science Translational Medicine.
Researchers at the University of Chicago have developed a genetic screening tool that identified two key factors that allow the influenza virus to infect human lung cells. The technique uses new gene editing tools to create a library of modified cells, each missing a different gene, allowing scientists to see which changes impact their response to flu. This in turn could identify potential targets for antiviral drugs.
In the April 5, 2018 issue of the journal Cell, researchers push for greater emphasis on the neglected viral-surface influenza protein neuraminidase. For decades, flu vaccines have concentrated on hemagglutinin. The authors maintain that a focus on neuraminidase could lower infection rates and lessen severity.
Scientists at The Scripps Research Institute have discovered a new aspect of the flu virus and how it interacts with antibodies in the lungs.
A team of researchers including scientists from the University of Georgia has found that the resurgence of pertussis, more commonly known as whooping cough, in the U.S. is a predictable consequence of incomplete coverage with a highly effective vaccine. This finding goes against pervasive theories on why we are seeing a steady increase in the disease even though the vaccine is given at an early age.
Researchers and public health officials have struggled to explain the resurgence of whooping cough in the United States since the late 1970s, and the suspected shortcomings of the current generation of vaccines are often blamed. But a new University of Michigan-led study concludes that the resurgence of the highly contagious respiratory disease is the result of factors—including a phenomenon known as the honeymoon period—that began in the middle of the last century, long before the latest vaccines were introduced in the late 1990s.
A distinguished molecular virologist will lead the University of Pittsburgh’s Center for Vaccine Research, which focuses on the development of diagnostics, therapeutics and vaccines for infectious diseases that pose risks to global public health.
An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.
Georgetown University and CEPI U.S. – the Coalition for Epidemic Preparedness Innovations U.S. – today announce a new agreement to explore joint cooperative academic and research initiatives.
Research led by the University of Southampton is helping governments in low-income countries strengthen their capacity to build and use population maps, to plan for the future and respond to emergencies.
Vanderbilt University Medical Center is recruiting volunteers to participate in a national study of an investigational vaccine against the H7N9 influenza virus, also known as “bird flu.”
UGA researcher Ted Ross shares his thoughts on the future of flu prevention
The Consortium of Universities for Global Health (CUGH), the Perlmutter Cancer Center, and the Department of Population Health at NYU Langone Health are issuing the “New York Challenge,” an ambitious campaign to end cervical cancer worldwide.
Nearly half of adolescents aren’t receiving a pair of vaccines to prevent a virus many of them will get.
Mandatory flu vaccines for health care workers improve participation by as much as 30 percent and reduce absenteeism during critical periods of patient surges by about 6 percent, findings from a multi-institutional study show.
Better targeting at the district and neighborhood level could make anti-cholera efforts much more effective and dramatically reduce the burden of this disease, according to two new studies led by scientists at Johns Hopkins Bloomberg School of Public Health.
The secret to stopping some viruses from making people sick might be hidden in red wine and chocolate — but that doesn't mean having more bonbons and vino is in order, Kansas State University researchers say.
In this issue, find research on gun storage, LARCs and abortion, flu vaccine disparities, air pollution disparities, Brazil birthrate after Zika and more
Researchers from the University of Chicago, Harvard University and others show that poor immune responses, not egg adaptions, may explain the low effectiveness of the vaccine that year.
With this year’s severe flu season, one statistic is especially chilling. Each year, around 50 percent of all children under 5 years old who die from the flu were previously healthy, according to the Centers for Disease Control and Prevention (CDC). Adults who die from the flu, on the other hand, typically had a medical condition that increased their risk of mortality. A new study published in the Journal of Immunology offers new insights as to why healthy children are much more vulnerable. It also opens new opportunities for treatment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right